Our Blog
The Rare Journey Needs a Special Pharmacy Partner
Drug Channels Institute | March 27, 2026
PANTHERx Rare’s CEO, Bansi Nagji, authored an insightful guest post for Drug Channels Institute titled, “The Rare Journey Needs a Special Pharmacy Partner.” He makes...
From Insight to Intention: What the Rare Disease Community Is Asking of Itself
March 24, 2026
I recently had the privilege to serve as a Co-Chair of this year’s Access USA Rare Disease Summit, which means I had the privilege of...
Patient-centric care needs to be at the epicenter of CGT expansion
February 18, 2026
Dr. Jastrab speaks on a panel at Advanced Therapies Week in February 2026. By Abigail Jastrab, PharmD, BCPS Director, Patient Engagement and Clinical Innovation As...
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
Drug Channels Institute | January 9, 2026
In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard...
PANTHERx Rare Submits Comment Letter for FDA’s Rare Disease Innovation, Science and Exploration (RISE) Workshop Series
January 5, 2026
Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public...
New article from PANTHERx CEO, Bansi Nagji, explores how hyper-personalization is reshaping the way we approach rare disease care
Drug Channels Institute | September 12, 2025
Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights...
Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner
Drug Channels Institute | February 7, 2025
Today’s guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. Richard outlines the key factors for commercialization success when...